Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Clearmind Medicine

06/02/2026 13:25

** Shares of  drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket

**  Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders

** CNMD's shares were up 20% at $1.7 premarket

** CNMD's  MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co

**  Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery

** PLRZ shares down over 99%, CNMD down ~41% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))